TOCQUEVILLE ASSET MANAGEMENT L.P. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2016. The put-call ratio across all filers is 0.81 and the average weighting 0.0%.

Quarter-by-quarter ownership
TOCQUEVILLE ASSET MANAGEMENT L.P. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2019$365,000
+31.8%
28,130
+23.9%
0.01%
+25.0%
Q1 2019$277,000
-1.4%
22,705
-8.0%
0.00%0.0%
Q4 2018$281,000
-48.3%
24,685
-1.5%
0.00%
-42.9%
Q3 2018$544,000
+22.8%
25,0600.0%0.01%
+16.7%
Q2 2018$443,000
+19.7%
25,060
+42.7%
0.01%
+20.0%
Q1 2018$370,000
+6.3%
17,560
-27.0%
0.01%
+25.0%
Q4 2017$348,000
+79.4%
24,060
+95.2%
0.00%
+100.0%
Q3 2017$194,000
+26.8%
12,3250.0%0.00%0.0%
Q2 2017$153,000
-29.5%
12,325
-7.5%
0.00%
-33.3%
Q1 2017$217,000
-4.8%
13,325
-11.9%
0.00%0.0%
Q4 2016$228,000
-83.7%
15,125
-83.5%
0.00%
-82.4%
Q3 2016$1,399,000
-79.1%
91,775
-46.8%
0.02%
-58.5%
Q2 2016$6,690,000
+209.9%
172,350
+121.9%
0.04%
+41.4%
Q1 2016$2,159,000
-48.0%
77,675
+0.6%
0.03%
-48.2%
Q4 2015$4,151,000
+55.2%
77,175
+15.6%
0.06%
+55.6%
Q3 2015$2,674,00066,7750.04%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2016
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders